Ainhoa Madariaga/comunidad.madrid
Feb 8, 2025, 19:15
Ainhoa Madariaga: Rethinking control arms in platinum-resistant/refractory ovarian cancer
Ainhoa Madariaga, Medical Oncologist at University Hospital October 12, shared an article by Husam A. Alqaisi, et al. on X:
“Rethinking control arms in PlatR ovarian cancer.
Investigator initiated Phase II trial:
Anetumab+Bev vs weekly Taxol +Bev.
Weekly Taxol+ Bev: mPFS 12.7m, ORR 65%.
Role of IL6?”
Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant/refractory high grade ovarian cancer (NCI trial).
Authors: Husam A. Alqaisi, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 8, 2025, 19:10
Feb 8, 2025, 19:05
Feb 8, 2025, 18:58
Feb 8, 2025, 18:56
Feb 8, 2025, 17:58